---

2011 年

In English


Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Valentine ME, Khursigara G, Ozawa K, Omine M. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS Clinical Trial.
Int J Hematol 93:36-46, 2011

Kashiwagi H, Kiyomizu K, Kamae T, Nakazawa T, Tadokoro S, Takiguchi S, Doki Y, Kanakura Y, Tomiyama Y. Molecular analysis of a patient with type I Glanzmann thrombasthenia and clinical impact of the presence of anti-αIIbβ3 alloantibodies.
Int J Hematol 93:106-111, 2011

Tadokoro S, Nakazawa T, Kamae T, Kiyomizu K, Kashiwagi H, Honda S, Kanakura Y, Tomiyama Y. A potential role for α-actinin in inside-out αIIbβ3 signaling.
Blood 117:250-258, 2011

Kamae T, Kiyomizu K, Nakazawa T, Tadokoro S, Kashiwagi H, Honda S, Kanakura Y, Tomiyama Y. Bleeding tendency and impaired platelet function in a patient carrying a heterozygous mutation in the thromboxane A2 receptor.
J Thromb Haemost 9:1040-1048, 2011

Saitoh N, Oritani K, Saito K, Yokota T, Ichii M, Sudo T, Fujita N, Nakajima K, Okada M, Kanakura Y. Identification of functional domains and novel binding partners of STIM proteins.
J Cell Biochem 112:147-156, 2011

Fujita J, Mizuki M, Otsuka M, Ezoe S, Tanaka H, Satoh Y, Fukushima K, Tokunaga M, Matsumura I, Kanakura Y. Myeloid neoplasm-related gene abnormalities differentially affect dendritic cell differentiation from murine hematopoietic stem/progenitor cells.
Immunol Lett 136:61-73, 2011

Otsuka M, Mizuki M, Fujita J, Kang S, Kanakura Y. Constitutively active FGFR3 Lys650Glu mutation enhances the bortezomib-sensitivity in plasma cell malignancy.
Anticancer Res 31:113-122, 2011

Shibata M, Ezoe S, Oritani K, Matsui K, Tokunaga M, Fujita N, Saito Y, Takahashi T, Hino M, Matsumura I, Kanakura Y. Predictability of the response to tyrosine kinase inhibitors via in vitro analysis of Bcr-Abl phosphorylation.
Leuk Res 35:1205-1211, 2011

Saito Y, Shibayama H, Tanaka H, Tanimura A, Kanakura Y. A cell-death-defying factor, anamorsin mediates cell growth through inactivation of PKC and p38MAPK.
Biochem Biophys Res Commun 405:303-307, 2011

Saito Y, Shibayama H, Tanaka H, Tanimura A, Matsumura I, Kanakura Y. PICOT is a molecule which binds to anamorsin.
Biochem Biophys Res Commun 408:329-333, 2011

Sasaki S, Hashimoto K, Nakatsuka S, Hasegawa M, Nakano T, Nagata S, Kanakura Y, Hayashi N. Plasmablastic extramedullary plasmacytoma associated with epstein-barr virus arising in an immunocompetent patient with multiple myeloma.
Intern med 50:2615-2620, 2011

Wada N, Ikeda J, Hori Y, Fujita S, Ogawa H, Soma T, Sugiyama H, Fukuhara S, Kanamaru A, Hino M, Kanakura Y, Morii E, Aozasa K. Epstein-barr virus in diffuse large B-cell lymphoma in immunocompetent patients in Japan is as low as in Western Countries.
J Med Virol 83:317-321, 2011

Zaki MA, Wada N, Kohara M, Ikeda J, Hori Y, Fujita S, Ogawa H, Sugiyama H, Hino M, Kanakura Y, Morii E. Presence of B-cell clones in T-cell lymphoma.
Eur J Haematol 86:412-419, 2011

Park KA, Yun N, Shin DI, Choi SY, Kim H, Kim WK, Kanakura Y, Shibayama H, Oh YJ. Nuclear translocation of anamorsin during drug-induced dopaminergic neurodegeneration in culture and in rat brain.
J Neural Transm 118:433-444, 2011

Hashimoto T, Sakata Y, Fukushima K, Maeda T, Arita Y, Shioyama W, Nakaoka Y, Hori Y, Morii E, Aozasa K, Kanakura Y, Yamauchi-Takihara K, Komuro I. Pulmonary arterial hypertension associated with chronic active Epstein-Barr virus infection.
Intern Med 50:119-24, 2011

Togi S, Ikeda O, Kamitani S, Nakasuji M, Sekine Y, Muromoto R, Nanbo A, Oritani K, Kawai T, Akira S, Matsuda T. Zipper-interacting protein kinase (ZIPK) modulates canonical Wnt/beta-catenin signaling through interaction with Nemo-like kinase and T-cell factor 4 (NLK/TCF4).
J Biol Chem 286:19170-19177, 2011

Ikeda O, Mizushima A, Sekine Y, Yamamoto C, Muromoto R, Nanbo A, Oritani K, Yoshimura A, Matsuda T. Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells.
Cancer Sci 102:756-761, 2011

Ishizaki M, Akimoto T, Muromoto R, Yokoyama M, Ohshiro Y, Sekine Y, Maeda H, Shimoda K, Oritani K, Matsuda T. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo.
J Immunol 187:181-189, 2011

Ishizaki M, Muromoto R, Akimoto T, Ohshiro Y, Takahashi M, Sekine Y, Maeda H, Shimoda K, Oritani K, Matsuda T. Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice.
Int Immunol 23:575-582, 2011

Kamitani S, Togi S, Ikeda O, Nakasuji M, Sakauchi A, Sekine Y, Muromoto R, Oritani K, Matsuda T. Krüppel-associated box-associated protein 1 negatively regulates TNF-α-induced NF-κB transcriptional activity by influencing the interactions among STAT3, p300, and NF-κB/p65.
J Immunol 187:2476-2483, 2011

Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review.
Int J Hematol 93:329-335, 2011

Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, Kirito K, Yonemura Y, Mori S, Usuki K, Iwato K, Hashino S, Wei H, Lizambri R. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.
Int J Hematol 94:71-80, 2011

Torita S, Suehisa E, Kawasaki T, Toku M, Takeo E, Tomiyama Y, Nishida S, Hidaka Y. Development of a new modified Bethesda method for coagulation inhibitors: the Osaka modified Bethesda method.
Blood Coagul Fibrinolysis 22:185-189, 2011

Kunishima S, Kashiwagi H, Otsu M, Takayama N, Eto K, Onodera M, Miyajima Y, Takamatsu Y, Suzumiya J, Matsubara K, Tomiyama Y, Saito H. Heterozygous ITGA2B R995W mutation inducing constitutive activation of the αIIbβ3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia.
Blood 117:5479-5484, 2011

Sasamoto N, Tomimatsu T, Nagamine K, Oshida M, Kashiwagi H, Koyama S, Kanagawa T, Arahori H, Tomiyama Y, Kimura T. Fetal and neonatal anemia associated with anti-Jr(a) : A case report showing a poorly hemolytic mechanism.
J Obstet Gynaecol Res 37:1132-1136, 2011

Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, Nagai T, Ohnishi K, Maeda M, Matsuda A, Amagasaki T, Yanada M, for the Japanese AMN107/2303 Study Group. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd.
Int J Hematol 93:624-632, 2011

Zaki MA, Wada N, Ikeda J, Shibayama H, Hashimoto K, Yamagami T, Tatsumi Y, Tsukaguchi M, Morii E, Aozasa K. Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma.
Virchows Archiv 459:361-366, 2011

Nishida S, Kawasaki T, Kashiwagi H, Morishima A, Hishitani Y, Kawai M, Hirano T, Ishii T, Hagihara K, Shima Y, Narazaki M, Ogata A, Oka Y, Kishimoto T, Tanaka T. Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab.
Mod Rheumatol 21:420-422, 2011

Burnette AD, Nimjee SM, Batchvarova M, Zennadi R, Telen MJ, Nishimura J, Sullenger BA. RNA aptamer therapy for vaso-occlusion in sickle cell disease.
Nucleic Acid Ther 21:275-283, 2011


In Japanese


織谷健司, 金倉 譲. 造血器腫瘍に対する分子標的治療薬同士の併用化学療法(造血器癌). 医薬ジャーナル 47:96-100, 2011

織谷健司, 金倉 譲. 第5章 血液腫瘍. がんの浸潤・転移(高井義美編), 南山堂, 東京, pp44-53, 2011

織谷健司. World Report-16th Congress of the European Hematology Association. Trends in Hematological Malignancies 3:42-43, 2011

織谷健司. 骨髄異形成症候群の現状 暗闇からの脱出. わいわいHome No.7:1, 2011

冨山佳昭. 特発性血小板減少性紫斑病 - 最近の話題. 細胞 43:18-21, 2011

冨山佳昭. 第II章 薬物編 1. 抗血小板薬. 抗血栓薬の最前線-基礎と臨床-(斎藤英彦編), 医薬ジャーナル社, 大阪, 2011, pp36-72

冨山佳昭. 血小板凝集能の標準化に対して、国内、国外でどのような取り組みをしていますか. 血栓と循環 19:65-66, 2011

冨山佳昭. 血小板の活性化機能:ADPの果たす役割. 人工血液 18:151-153, 2010 (2011年に発行)

冨山佳昭. 特発性血小板減少性紫斑病 - 最近の話題. Medicament News 2049:5-6, 2011

冨山佳昭. II. 臨床 脾臓と関連した疾患. 成人を中心とした特発性血小板減少性紫斑病. 脾臓 -基礎と臨床- (冲永功太編), へるす出版, 東京, 2011, pp131-135

冨山佳昭. 出血斑の種類と病因. わかりやすい血栓と止血の臨床(日本血栓止血学会編),南江堂, 東京, 2011, pp70-72

冨山佳昭. P2Y12受容体阻害抗血小板薬. カレントテラピー 29:59-63, 2011

冨山佳昭. 今後の抗血小板療法. 血栓と循環 19:305-310, 2011

冨山佳昭. 特発性血小板減少性紫斑病(ITP)の治療戦略と血小板増加薬の適応. 血液フロンティア 21:997-1003, 2011

冨山佳昭. 特発性血小板減少性紫斑病(ITP)の病態と新規治療法. SRL宝函 32:33-42, 2011

冨山佳昭. トロンボポエチン受容体作動薬による難治性ITPの治療. 臨床血液 52:627-632, 2011

冨山佳昭. 新規抗血小板薬の開発. 脈管学 51:301-307, 2011

冨山佳昭. 血管障害による出血性疾患:血管性紫斑病. 血液専門医テキスト(日本血液学会編), 南江堂, 東京, 2011, pp359-361

冨山佳昭. 特発性血小板減少性紫斑病. 血液専門医テキスト(日本血液学会編), 南江堂, 東京, 2011, pp362-365

柴山浩彦, 金倉 譲. 悪性リンパ腫の診断と分類. クリニシアン 58:43-48, 2011

柴山浩彦. 質疑応答「疲労感を訴える高齢女性の治療」. 日本医事新報 No.4530:91-92, 2011

柴山浩彦. 第13章 白血病における新しい予後予測/治療効果予測因子と今後の試験デザイン 第3節 白血病における試験デザインの傾向と今後求められる試験デザイン. がんの新しいバイオマーカー/予測因子による個別化医療時代に求められる抗がん剤開発(佐藤章弘編), 技術情報協会,東京,2011,pp356-365

柏木浩和,冨山佳昭. 特発性血小板減少性紫斑病(ITP). 専門医のための薬物療法Q&A (小松則夫,片山直之,冨山佳昭編),中外医学社,東京,2011, pp314-323

柏木浩和. GPVI(Glycoprotein VI). Vascular Medicine 7:67-71, 2011

西村純一, 金倉 譲. 発作性夜間血色素尿症(PNH)の病因・病態・治療. 日本内科学会雑誌 100:1994-1999, 2011

西村純一, 金倉 譲. 発作性夜間ヘモグロビン(血色素)尿症と抗体薬治療. 日本医師会雑誌 140:1429-1432, 2011

西村純一, 金倉 譲. 発作性夜間ヘモグロビン尿症. 難治性貧血の診療ガイド(『難治性貧血の診療ガイド』編集委員会編), 南江堂, 東京, 2011, pp93-130

西村純一, 金倉 譲. 発作性夜間ヘモグロビン尿症の診断と治療のマネージメント. 日本血栓止血学会誌 22:186-193, 2011

西村純一. 発作性夜間ヘモグロビン尿症. 今日の治療指針 2011年版(山口 徹, 北原光夫, 福井次矢編), 医学書院, 東京, 2011, pp584-585

西村純一. 発作性夜間ヘモグロビン尿症. Medicament News 2046:6-7, 2011

西村純一. PNHの最新の治療. 臨床血液 52:103-112, 2011

西村純一. 発作性夜間ヘモグロビン尿症. 最新医学 別冊 再生不良性貧血(小澤敬也編), 最新医学社, 東京, 2011, pp66-74

植田康敬, 西村純一. 発作性夜間ヘモグロビン尿症(PNH)に対するeculizumab治療. Annual Review血液2011(高久史麿, 小澤敬也, 坂田洋一, 金倉 譲, 小島勢二編), 中外医学社, 東京, 2011, pp65-72

植田康敬, 西村純一. 発作性夜間ヘモグロビン尿症. Mebio 28:82-91, 2011

山本正樹, 西村純一. 発作性夜間ヘモグロビン尿症(PNH)に対するエクリズマブ治療. 最新医学 66:124-128, 2011

山本正樹, 西村純一. 発作性夜間ヘモグロビン尿症の新しい診断と治療. Medical Practice 28:2173-2175, 2011

岸本 望, 高尾徹也, 山本圭介, 辻畑正雄, 野々村祝夫, 山本正樹, 水木満佐央, 原 恒男. HoLEPにて診断された前立腺原発悪性リンパ腫の1例. 泌尿器科紀要 57:445-449, 2011

西山美保, 林 悟, 兜森 修, 山西八郎, 末久悦次, 倉田義之, 柏木浩和, 冨山佳昭. 多項目自動血球分析装置XE-5000を用いた幼若血小板比率(IPF%)測定における抗凝固剤と保存温度の影響-抗凝固剤CTADと室温保存の有用性-. 臨床病理 59:452-458, 2011

池田珠世, 押田眞知子, 帰山ともみ, 櫻木美基子, 館農美香, 中尾まゆみ, 清川知子, 青地 寛, 永峰啓丞, 冨山佳昭. 廃棄血削減への取り組み-過去6年廃棄理由の解析-.日本輸血細胞治療学会誌 57:484-489, 2011